Data presented in partnership with T1D Exchange at the 75th Annual American Diabetes Association (ADA) Scientific Sessions support the efficacy and safety of needle-free glucagon nasal powder (GNP) for the treatment of severe hypoglycemia in youth with type 1 diabetes. Read the T1D press release here.